Bradley Evan Burnam
Known title: Chief Executive OfficerCIK: 0002087366
Associated companies
Transaction History
| TTRX | ▼ Sell | Gift | 300,000 | $0 | 5/28/2026 | View on chart |
| TTRX | ▼ Sell | Gift | 300,000 | $0 | 5/28/2026 | View on chart |
| TTRX | ▼ Sell | Gift | 300,000 | $0 | 5/28/2026 | View on chart |
| TTRX | ▼ Sell | Gift | 300,000 | $0 | 5/28/2026 | View on chart |
| TTRX | ▼ Sell | Gift | 300,000 | $0 | 4/2/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Lucid Capital initiates coverage on TTRX with $24 target
Lucid Capital Markets has begun tracking Turn Therapeutics, assigning a Buy rating and setting a price target of $24. This new analyst note adds to the current average target of $25. The stock is currently trading well below its 52-week high, providing context for the new coverage initiation.
Lucid Capital initiates coverage on TTRX with $24 target. Lucid Capital Markets has begun tracking Turn Therapeutics, assigning a Buy rating and setting a price target of $24. This new analyst note adds to the current average target of $25. The stock is currently trading well below its 52-week high, providing context for the new coverage initiation.